This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arena Pharmaceuticals Inc (ARNA)

NASDAQ: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 38.33M 36.97M 81.39M 27.59M
Cost of Sales 3.00M 7.76M 6.18M 3.67M
Gross Operating Profit 35.33M 29.21M 75.21M 23.92M
Selling, General, and Administrative Expenses 35.97M 34.14M 31.68M 26.23M
Research & Development 88.41M 100.35M 66.47M 54.11M
Operating Income before D & A (EBITDA) -89.05M -105.27M -22.93M -56.42M
Depreciation & Amortization 10.18M 9.30M 8.34M 11.26M
Interest Income 158.00K 83.00K 89.00K 119.00K
Other Income - Net 1.89M 51.60M 10.50M -19.36M
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -101.15M -62.89M -20.68M -86.93M
Interest Expense 6.83M 6.92M 7.09M 9.12M
Pre-Tax Income -107.98M -69.81M -27.77M -96.05M
Income Taxes 0.00 0.00 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -107.98M -60.51M -19.43M -85.48M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -107.98M -60.51M -19.43M -85.48M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -107.98M -60.51M -19.43M -85.48M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-104.01M -60.51M -19.43M -85.48M
Preferred Dividends
Net Income Available To Common -107.98M -60.51M -19.43M -85.48M
Basic EPS from Continuing Ops. -0.45 -0.28 -0.09 -0.45
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -0.45 -0.28 -0.09 -0.45
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -0.45 -0.28 -0.09 -0.45
Basic Normalized Net Income/Share -0.43 -0.28 -0.09 -0.45
EPS fr Continuing Ops. -0.45 -0.28 -0.09 -0.45
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -0.45 -0.28 -0.09 -0.45
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -0.45 -0.28 -0.09 -0.45
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.43 -0.28 -0.09 -0.45
Dividends Paid per Share 0.00 0.00 0.00 0.00
ARNA News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ARNA Arena Pharmaceuticals Inc

Chart of ARNA

Analysts Ratings for ARNA

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 3 3 2 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET ARNA ANALYST REPORT

ARNA Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs